Janux Therapeutics Inc. Insider Trading

JANX

Last 12 months

Insiders sold 557K and bought nothing on the open market.

38% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Oct 2024.

Net open-market

−557K

0 buys · 10 sales

Under a 10b5-1 plan

38%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Oct 2024

Oct 18, 2024

Get an email when JANX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 2	Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr	SoldNo plan	4,059	$14.03	57K	5.1%	Form 4
May 11	Maria Dobek Vice President, Accounting	SoldNo plan	2,038	$14.17	29K	5.9%	Form 4
Jan 2	Zachariah McIver Chief Medical Officer	SoldNo plan	2,714	$13.73	37K	4.9%	Form 4
Jan 2	Maria Dobek Vice President, Accounting	SoldNo plan	1,462	$13.73	20K	4.1%	Form 4
Jan 2	Thomas Diraimondo Chief Scientific Officer	SoldNo plan	2,505	$13.73	34K	1.6%	Form 4
Jan 2	Charles M. Winter Chief Technical Officer	SoldNo plan	2,401	$13.73	33K	2.2%	Form 4
Jan 2	Andrew Hollman Meyer Chief Business Officer	SoldNo plan	1,879	$13.73	26K	2.2%	Form 4
Jan 2	David Alan Campbell President and CEO	SoldNo plan	8,072	$13.73	111K	2.1%	Form 4
Dec 1, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan 2 parts	3,333	$32.98 average	110K	3.8%	Form 4
Nov 14, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan	3,333	$30.00	100K	3.8%	Form 4
Oct 28, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan	16,665	$30.06	501K	17%	Form 4
May 1, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan 2 parts	3,333	$32.03 average	107K	3.9%	Form 4
Apr 21, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan	3,334	$30.00	100K	3.9%	Form 4
Mar 5, 2025 – Mar 7, 2025	RA Capital Healthcare Fund LP Large holder	Bought 4 parts	824,041	$30.75 average	$25.3M	8.8%	Form 4
Mar 3, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan 2 parts	3,334	$32.14 average	107K	3.9%	Form 4
Feb 3, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan 3 parts	3,334	$42.29 average	141K	3.9%	Form 4
Jan 7, 2025	David Alan Campbell President and CEO	Sold10b5-1 plan	5,000	$60.00	300K	1.7%	Form 4
Jan 2, 2025	Andrew Hollman Meyer Chief Business Officer	Sold10b5-1 plan 5 parts	13,334	$54.88 average	732K	14%	Form 4
Dec 24, 2024	David Alan Campbell President and CEO	Sold10b5-1 plan	25,000	$56.19	$1.4M	10%	Form 4
Dec 3, 2024	David Alan Campbell President and CEO	Sold10b5-1 plan	15,000	$67.00	$1M	5.8%	Form 4
Nov 25, 2024	David Alan Campbell President and CEO	Sold10b5-1 plan 2 parts	25,000	$51.59 average	$1.29M	8.9%	Form 4

Jun 2No plan
Janeen Noel Doyle
Chief Corp. & Bus. Dev. Ofcr · sold 4,059 at $14.03
57K
5.1% of stake
May 11No plan
Maria Dobek
Vice President, Accounting · sold 2,038 at $14.17
29K
5.9% of stake
Jan 2No plan
Zachariah McIver
Chief Medical Officer · sold 2,714 at $13.73
37K
4.9% of stake
Jan 2No plan
Maria Dobek
Vice President, Accounting · sold 1,462 at $13.73
20K
4.1% of stake
Jan 2No plan
Thomas Diraimondo
Chief Scientific Officer · sold 2,505 at $13.73
34K
1.6% of stake
Jan 2No plan
Charles M. Winter
Chief Technical Officer · sold 2,401 at $13.73
33K
2.2% of stake
Jan 2No plan
Andrew Hollman Meyer
Chief Business Officer · sold 1,879 at $13.73
26K
2.2% of stake
Jan 2No plan
David Alan Campbell
President and CEO · sold 8,072 at $13.73
111K
2.1% of stake
Dec 1, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 3,333 at avg $32.98
110K
3.8% of stake
Nov 14, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 3,333 at $30.00
100K
3.8% of stake
Oct 28, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 16,665 at $30.06
501K
17% of stake
May 1, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 3,333 at avg $32.03
107K
3.9% of stake
Apr 21, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 3,334 at $30.00
100K
3.9% of stake
Mar 5, 2025 – Mar 7, 2025
RA Capital Healthcare Fund LP
Large holder · bought 824,041 at avg $30.75
$25.3M
8.8% of stake
Mar 3, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 3,334 at avg $32.14
107K
3.9% of stake
Feb 3, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 3,334 at avg $42.29
141K
3.9% of stake
Jan 7, 202510b5-1 plan
David Alan Campbell
President and CEO · sold 5,000 at $60.00
300K
1.7% of stake
Jan 2, 202510b5-1 plan
Andrew Hollman Meyer
Chief Business Officer · sold 13,334 at avg $54.88
732K
14% of stake
Dec 24, 202410b5-1 plan
David Alan Campbell
President and CEO · sold 25,000 at $56.19
$1.4M
10% of stake
Dec 3, 202410b5-1 plan
David Alan Campbell
President and CEO · sold 15,000 at $67.00
$1M
5.8% of stake
Nov 25, 202410b5-1 plan
David Alan Campbell
President and CEO · sold 25,000 at avg $51.59
$1.29M
8.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch JANX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with JANX

CompareIntrinsic value

BGMBGM Group Ltd.

$8.81-7.65%26

ZYBTZhengye Biotechnology Holding Ltd.

$1.37+2.24%9

STOKStoke Therapeutics Inc.

$27.45+1.70%25

SCYXScynexis, Inc.

$3.84-2.54%40

EVFMEvofem Biosciences Inc.

$0.01+0.00%15

FHTXFoghorn Therapeutics Inc.

$2.10-1.41%40

SLGLSol-Gel Technologies Ltd.

$66.00+3.43%65

JAGXJaguar Health, Inc.

$0.50-10.61%40

Held by ETFs

JANX is in 26 US ETFs. The largest of them, with JANX's weight in each:

Spot a number that looks wrong? Check it in JANX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing JANX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.